Project Grant HT94252310199

This $527,159 Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research by Brigham & Women's Hospital Inc. to investigate the relationship between DNA damage, cell fate plasticity, and breast cancer initiation in BRCA1 mutation carriers. The research aims to determine if BRCA1-deficient luminal mammary epithelial cells acquire a fetal mammary stem cell-like epigenetic state and stemness program, potentially driven by inadequate repair of...

This $543,221 Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) supports research at the Albert Einstein College of Medicine to study the cellular and molecular mechanisms underlying lineage plasticity in basal-like breast cancer (BLBC). The key objectives are to: Define the critical de-differentiated cell states driving BLBC progression and explore therapeutic strategies to target these cells for cancer interception. This involves using mouse...

This federal Project Grant award of $219,491 from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) aims to characterize the non-genetic mechanisms driving dynamic and heterogeneous expression of the HER2 gene in breast cancer. The research, conducted by Emory University, will leverage cell culture models and single-cell multi-omics analyses to define exogenous and intrinsic factors influencing HER2 plasticity, as well as understand the transcriptional and chromatin...

This $187,887 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) will support research by Dr. Natasha Weiser at Stanford University to investigate the role of extrachromosomal DNA (ecDNA) in HER2-amplified breast cancer. The key objectives are to: 1) examine how HER2 ecDNA drives transcription-replication conflicts and replication stress, 2) assess the impact of HER2 ecDNA on response to anti-HER2 therapies like trastuzumab, and 3) determine...

This $398,728 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports the development of a novel homologous recombination (HR) inhibitor, CP-8, to sensitize triple-negative breast cancer (TNBC) cells to DNA-damaging agents. The project aims to examine the synergy of CP-8 with various DNA-damaging therapies, including PARP inhibitors and ionizing radiation, in TNBC cell lines, patient-derived xenograft models, and in vivo...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding of $216,972 to Temple University to conduct research on understanding and targeting unique vulnerabilities in small cell lung cancer (SCLC). The key products and services to be delivered under this 4-year award include: Determining the mechanistic underpinnings of the increased replication stress observed in SCLC, including the role of low levels of the LMNA nuclear structural...

This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $122,032 to Weill Medical College of Cornell University to conduct research focused on understanding the role of aberrant splicing and isoform expression in cancer cell heterogeneity and its potential as a target for cancer immunotherapy. The research aims to: 1) Characterize mutations in splicing factors and identify tumor-specific isoforms in myelodysplastic syndromes, 2) Explore...

This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $514,196 to the Dana-Farber Cancer Institute (DFCI) to investigate IGF2BP1 as a novel therapeutic target for Ewing sarcoma, an aggressive pediatric bone cancer. The key products/services to be delivered under this award include: Using CRISPR-Cas9 genome editing to validate IGF2BP1 as an Ewing sarcoma dependency in cell lines and patient-derived xenograft models. This will include...

This $432,614 federal Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research at Duke University to investigate the relationship between chromosomal instability, loss of chromosome 17p, and sensitivity to depletion of the mitotic regulator NDE1 in advanced, metastatic cancers. The research aims to define the link between NDE1 dependence, 17p loss, and chromosomal instability, characterize NDE1's role in chromosome segregation, and...

The Project Grant award R35CA293978, provided by the National Cancer Institute (CFDA 93.393 Cancer Cause and Prevention Research), supports research to identify the mechanisms driving rapid evolution of cancer genomes. The $942,442 award to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, MA will fund investigations into two catastrophic mutational processes in cancer, chromothripsis and chromoplexy. The research aims to better understand the mechanisms of chromosome fragmentation, DNA...